GlassScriptPhysician profile
Kushan Radadia
NPI 1275949992
$6,199.16
in general payments reported to CMS, 2019-2025
38 companies · $1,633 in 2025
The $1,633 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $192 · 2021: $770 · 2022: $484 · 2023: $961 · 2024: $1,408 · 2025: $1,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103 · Honoraria: $486 · Consulting Fee: $375 · Education: $23.40 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,102.59 |
| Honoraria | $486.00 |
| Consulting Fee | $375.00 |
| Education | $23.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,002.29 | 2021-2025 | Urolift, Barrigel |
| Boston Scientific Corporation | $975.03 | 2019-2025 | Ams 700 |
| Endo Pharmaceuticals INC. | $510.74 | 2020-2024 | Xiaflex, Aveed |
| Medtronic, INC. | $461.92 | 2021-2025 | Interstim |
| Verathon INC. | $375.00 | 2025 | Npd Clinical Study |
| Astellas Pharma US INC | $321.34 | 2021-2025 | Xtandi, Veozah |
| Dendreon Pharmaceuticals LLC | $271.23 | 2021-2025 | Provenge |
| Sumitomo Pharma America, INC. | $225.77 | 2023-2025 | Orgovyx, Gemtesa |
| Tolmar, INC. | $217.45 | 2023-2025 | Jatenzo, Eligard |
| Convatec INC. | $193.03 | 2022-2025 | |
| C. R. Bard, INC. & Subsidiaries | $171.21 | 2024-2025 | Bard Urinary Drainage Bag |
| Coloplast Corp | $170.60 | 2021-2023 | Speedicath |
| Antares Pharma, INC. | $137.24 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Endo USA, INC. | $122.06 | 2024-2025 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $120.23 | 2021-2024 | Prolaris |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kushan Radadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.